Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs
暂无分享,去创建一个
L. Babiuk | M. Baca-Estrada | M. Foldvari | Praveen Kumar | M. Vega-López | R. Hecker | P. Willson | V. Alcón
[1] M. Levine,et al. Mucosally Delivered Salmonella Live Vector Vaccines Elicit Potent Immune Responses against a Foreign Antigen in Neonatal Mice Born to Naive and Immune Mothers , 2004, Infection and Immunity.
[2] L. Babiuk,et al. Biphasic lipid vesicles (Biphasix) enhance the adjuvanticity of CpG oligonucleotides following systemic and mucosal administration. , 2004, Current drug delivery.
[3] H. McShane,et al. Recombinant Modified Vaccinia Virus Ankara Administration and Boosting with a Bacille Calmette-Guérin Vaccine Using Mucosal of Mycobacterium tuberculosis Efficacy Against Enhanced Immunogenicity and Protective , 2003 .
[4] L. Babiuk,et al. Induction of protective immunity in pigs after immunisation with CpG oligodeoxynucleotides formulated in a lipid-based delivery system (Biphasix). , 2003, Vaccine.
[5] D. Kornbrust,et al. Oligodeoxynucleotide Studies in Primates: Antisense and Immune Stimulatory Indications , 2003, Toxicologic pathology.
[6] M. Baca-Estrada,et al. Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix) , 2002, The Journal of pharmacy and pharmacology.
[7] P. Payette,et al. Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. , 2002, FEMS immunology and medical microbiology.
[8] L. Babiuk,et al. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. , 2001, Antisense & nucleic acid drug development.
[9] R. Weeratna,et al. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. , 2001, Vaccine.
[10] K. Rosenthal,et al. Intranasal Immunization with CpG Oligodeoxynucleotides as an Adjuvant Dramatically Increases IgA and Protection Against Herpes Simplex Virus-2 in the Genital Tract1 , 2001, The Journal of Immunology.
[11] A. Krieg,et al. Immune effects and mechanisms of action of CpG motifs. , 2000, Vaccine.
[12] J. Mcghee,et al. Cutting Edge: The Mucosal Adjuvant Cholera Toxin Redirects Vaccine Proteins into Olfactory Tissues , 2000, The Journal of Immunology.
[13] H. Davis,et al. Intranasal Immunization of Mice with CpG DNA Induces Strong Systemic and Mucosal Responses That Are Influenced by Other Mucosal Adjuvants and Antigen Distribution , 2000, Molecular medicine.
[14] C. Partidos,et al. Antipeptide Antibody Responses following Intranasal Immunization: Effectiveness of Mucosal Adjuvants , 2000, Infection and Immunity.
[15] P. Couvreur,et al. Improvement of in vivo stability of phosphodiester oligonucleotide using anionic liposomes in mice. , 2000, Life sciences.
[16] K. Beagley,et al. Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract. , 2000, Molecular immunology.
[17] C. Bennett,et al. Enhanced anti-inflammatory activity of a liposomal intercellular adhesion molecule-1 antisense oligodeoxynucleotide in an acute model of contact hypersensitivity. , 2000, The Journal of pharmacology and experimental therapeutics.
[18] G. Dougan,et al. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. , 1999, Immunology today.
[19] H. Davis,et al. CpG DNA as mucosal adjuvant. , 1999, Vaccine.
[20] S. Ståhl,et al. Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. , 1999, Journal of biotechnology.
[21] M. Murtaugh,et al. Mucosal immunogenicity and adjuvanticity of cholera toxin in swine. , 1999, Vaccine.
[22] T. Hirst,et al. Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic. , 1999, Immunology today.
[23] I. Frazer,et al. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. , 1998, Virology.
[24] C. Alving,et al. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. , 1998, Journal of immunology.
[25] P. Ogra,et al. Mucosal responses to parenteral and mucosal vaccines. , 1998, Developments in biological standardization.
[26] M. Marinaro,et al. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. , 1996, The Journal of infectious diseases.
[27] A. Potter,et al. Molecular characterization of a protective outer membrane lipoprotein (OmlA) from Actinobacillus pleuropneumoniae serotype 1 , 1993, Infection and immunity.
[28] J. Mcghee,et al. The mucosal immune system: from fundamental concepts to vaccine development. , 1992, Vaccine.
[29] R. Chanock,et al. Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines , 1982, Infection and immunity.